AI-native personal health companies using continuous biomarker data
August 26 at 09:48 · $0.129 total
Here are 10 early-stage and lesser-known companies fitting the thesis of AI-native personal health powered by continuous biomarker data:
1. FlowBio — Develops a wearable sweat sensor that provides continuous, real-time hydration and sodium loss data for endurance athletes. Why it fits: Represents a shift from glucose to novel continuous biomarkers (sweat), backed by strong early traction with professional triathletes and a recent seed round.
2. Aktiia — Uses optical sensors and AI algorithms to provide continuous, 24/7 blood pressure monitoring via a sleek wristband. Why it fits: Strong clinical validation signal and a recent $30M funding round to tackle hypertension using passive, continuous data rather than point-in-time cuff measurements.
3. Vively — An Australian digital health app that pairs continuous glucose monitors (CGMs) with AI-driven lifestyle, sleep, and diet coaching. Why it fits: A genuinely early-stage (Seed) player capturing the international (non-US) metabolic health market, showing strong organic user growth by making CGM data actionable for non-diabetics.
4. Nix Biosensors — Creates a biometric patch that continuously analyzes sweat to deliver real-time hydration data and predictive AI insights to a smartphone or watch. Why it fits: Expands continuous monitoring beyond blood, showing strong signal through partnerships with major sports brands and early consumer adoption in the endurance market.
5. Biobeat — Provides an AI-powered wearable patch and smartwatch that continuously monitors 14 vital signs, including blood pressure, stroke volume, and cardiac output. Why it fits: Bridges clinical-grade continuous biomarkers with personal health, validated by FDA clearances for its proprietary AI-driven photoplethysmography (PPG) technology.
6. EnLiSense — Develops continuous, non-invasive wearable sensors that measure inflammatory biomarkers like cortisol and cytokines in sweat. Why it fits: An early-stage pioneer unlocking continuous stress and inflammation data—a massive, highly sought-after white space compared to standard metabolic tracking.
7. PKvitality — Building K’Watch, a smartwatch that uses micro-needles to continuously monitor glucose and lactate levels painlessly. Why it fits: A highly innovative hardware-AI play (currently in clinical trials) that brings continuous lactate monitoring—the holy grail for athletic performance—to the consumer market.
8. Biolinq — Develops an intradermal biosensor patch that continuously streams metabolic data using an array of microscopic electrochemical sensors. Why it fits: Strong venture signal (recent $58M financing) and an AI-ready approach to multi-analyte continuous sensing that aims to replace bulky traditional CGM form factors.
9. NuraLogix — Uses Transdermal Optical Imaging (TOI) and affective AI to extract continuous biomarkers (blood pressure, stress, HbA1c risk) simply by looking at a smartphone camera. Why it fits: A highly scalable, hardware-free approach to continuous biomarker collection, backed by a recent Series B and a robust AI patent portfolio.
10. Nutromics — Developing a continuous wearable patch using DNA-based aptamer sensors to track complex molecular targets in real-time. Why it fits: A cutting-edge, early-stage deep tech company pushing the boundaries of continuous biomarker data beyond simple molecules, laying the groundwork for highly personalized AI medicine.
***
2 Most Interesting White-Space Gaps Noticed While Sourcing:
- Continuous Hormone & Inflammation Tracking: The market is heavily saturated with continuous glucose monitors (CGMs) and cardiovascular wearables (HR/HRV). However, there is a massive gap in consumer-ready, continuous tracking for female sex hormones (estrogen/progesterone), stress hormones (cortisol), and inflammatory markers (cytokines). The AI models for metabolic health are mature, but AI models for continuous endocrinology are virtually non-existent.
- Closed-Loop AI Interventions: Almost all current companies are "read-only"—they collect continuous data and provide a dashboard or a notification. There is a significant white space for "read-write" or closed-loop systems where continuous biomarker data triggers automated physical interventions. Examples could include smart supplement dispensers that mix custom micro-nutrients based on morning sweat data, or dynamic grocery delivery APIs that automatically adjust your weekly cart based on your rolling 7-day glycemic response.
- January AI — Uses CGM data, food logs, and machine learning to model glucose responses and recommend personalized metabolic-health actions. Why it fits: AI is central to its “metabolic digital twin” product; it has commercial CGM programs and has raised substantial venture funding, while remaining smaller than major consumer-health platforms.
- Twin Health — Builds an AI “digital twin” from CGM, wearable, activity, and clinical data to provide personalized interventions for metabolic disease. Why it fits: A strong fit for the thesis because the product continuously ingests biomarkers and converts them into closed-loop coaching; it has shown traction through employer and provider deployments and significant institutional funding.
- Signos — Combines continuous glucose monitoring with AI-generated guidance on meals, exercise, sleep, and weight management. Why it fits: Consumer-facing and explicitly data-driven, with CGM as the core signal; the company has launched a subscription product and raised early-stage venture capital.
- Biolinq — Developing a minimally invasive, needle-free continuous glucose sensor designed to measure glucose in interstitial fluid. Why it fits: An early hardware/software company attacking the biggest bottleneck in continuous biomarker health—making monitoring easier and more scalable; it has attracted notable medtech and venture backing despite being pre-mass-market.
- Sano Intelligence — Developing a wearable continuous glucose monitor intended to provide glucose data without the traditional CGM insertion process. Why it fits: Early-stage and technically ambitious, with continuous biomarker collection as the product foundation; its differentiation is lower-friction access to glucose data rather than another coaching layer on top of existing CGMs.
- Aktiia — Uses a wearable optical sensor and algorithms to estimate blood pressure continuously rather than relying on occasional cuff measurements. Why it fits: It brings continuous cardiovascular biomarker monitoring to an important but underserved category; the company has obtained European regulatory clearance and built clinical and commercial partnerships.
- Empatica — Provides wearable biosensors and analytics for signals including heart rate, electrodermal activity, temperature, and motion. Why it fits: Its AI-enabled digital biomarkers are used in health and clinical settings, and its FDA-cleared EmbracePlus platform provides a credible regulatory and data-collection foundation, even though it is more clinical than consumer-oriented.
- Humanity — Uses continuous wearable data—such as resting heart rate, sleep, activity, and heart-rate variability—to estimate biological age and optimize health behaviors. Why it fits: The product is built around a longitudinal “rate of aging” signal rather than isolated tests; it is still relatively early and has raised venture funding while integrating data from major wearable platforms.
- ZOE — Combines CGM, microbiome, blood-fat, meal, and wearable data with machine learning to personalize nutrition recommendations. Why it fits: It is one of the clearest examples of an AI-native personal-health product built around multimodal biomarker data, with a large consumer dataset, peer-reviewed research, and international subscription traction.
- Levels — Uses CGM and wearable data to provide software-driven feedback on glucose, sleep, exercise, and metabolic health. Why it fits: Although more visible than most companies on this list, it remains a focused software-and-sensor health platform rather than a traditional provider; its signal is a sizable paid user base and sustained experimentation with personalized metabolic recommendations.
White-space gaps
- Continuous biomarkers beyond glucose: There is still limited consumer access to reliable, longitudinal measurements of blood pressure, inflammation, hormones, kidney function, and lipid metabolism without clinic visits or invasive sampling.
- Closed-loop intervention: Most products observe and coach but do not automatically connect biomarker changes to personalized treatment, nutrition delivery, medication adjustment, or clinician escalation. The opportunity is a trusted system that moves from sensing to validated action while preserving clinical safety.